In chronic lymphocytic leukemia (CLL), inhibiting mammalian target of rapamycin complex 1 (mTORC1) reduces eEF2 activity, leading to decreased synthesis of cell cycle proteins and halting CLL progression [15]. Here, EEF2 is linked to B-cell chronic lymphocytic leukemia.